{
    "nctId": "NCT00559507",
    "briefTitle": "Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery",
    "officialTitle": "A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Disease Control Rate (DCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed carcinoma of the breast\n\n  * Unresectable disease\n  * Locally advanced or metastatic (American Joint Committee on Cancer \\[AJCC\\] stage IV) disease\n* Estrogen receptor-negative and progesterone receptor-negative breast cancer defined as \\< 10% expression by immunohistochemistry (IHC)\n* Measurable disease, defined (per Response Evaluation Criteria in Solid Tumors \\[RECIST\\]) as \u2265 1 unidimensionally measurable lesion \u2265 20mm by conventional techniques or \u2265 10 mm by spiral computed tomography (CT) scan\n\n  * Measurable target lesions must not be in a previously irradiated field\n* Patients with locally advanced, unresectable disease must have progression of disease following no more than one first-line chemotherapy regimen\n* Patients with evidence of recurrent disease during or within 6 months after adjuvant chemotherapy will be considered to have failed one line of chemotherapy for metastatic disease\n* Human epidermal growth factor receptor 2 (HER2)-positive patients, defined as immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) amplification \\> 2.1, must have received trastuzumab (Herceptin\u00ae) in either the adjuvant or metastatic setting and have had recurrence or progression of disease, respectively\n* No known brain metastases\n* Male and female patients eligible\n* Menopausal status not specified\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) \u2264 2 (Karnofsky PS 60-100%)\n* Life expectancy \\> 3 months\n* Absolute neutrophil count \u2265 1,500/mcL\n* Platelet count \u2265 100,000/mcL\n* Hemoglobin \\> 9 g/dL\n* Total bilirubin normal\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \\[SGPT\\]) \u2264 2.5 x institutional upper limit of normal\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* Urine protein creatinine (UPC) ratio must be \u2264 1.0\n\n  * Patients with a UPC ratio \\> 1.0 must have a 24-hour urine protein \\< 1,000 mg to be eligible for study\n* Not pregnant or nursing\n* Women of child-bearing potential and men must use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to, during, and for 8 weeks after completion of study therapy\n* Able to understand and willing to sign a written informed consent document\n* No history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530\n* No QTc interval \u2265 500 msecs\n* No condition that impairs the ability to swallow AZD0530 tablets, including the following:\n\n  * Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation\n  * Prior surgical procedures affecting absorption\n  * Active peptic ulcer disease\n* No intercurrent cardiac dysfunction including, but not limited to, any of the following:\n\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Uncontrolled cardiac arrhythmia\n  * History of myocardial infarction within 6 months of treatment\n* No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements\n* No severe restrictive or obstructive lung disease according to baseline pulmonary function studies including any of the following pulmonary function test (PFT) parameters:\n\n  * Total lung capacity \\< 60%\n  * Forced vital capacity \\< 50%\n  * Forced expiratory volume in one second (FEV_1) \\< 50%\n  * Diffusion capacity of carbon monoxide (DLCO) \\< 50%\n  * Resting room air O_2 saturation \\< 92% or a decline in O_2 saturation \\> 4% with exercise\n* Patients with metastatic disease may have received no more than 1 prior chemotherapy regimen\n* No unresolved toxicity \u2265 grade 3 from agents received more than 3 weeks earlier\n* No chemotherapy, radiotherapy, or investigational therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study\n* No luteinizing hormone-releasing hormone agonists within 4 weeks prior to study entry\n* More than 7 days since prior and no concurrent use of specifically prohibited cytochrome P 450 3A4 (CYP3A4) agents\n* No concurrent megestrol acetate, even when prescribed for appetite stimulation\n* No other concurrent investigational or commercial agents for the treatment of breast cancer\n* No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients\n* No concurrent megestrol acetate",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}